Similarly, in the Clarity AD trial of lecanemab, APOE4 homozygous carriers had a higher incidence of ARIA-E (32.6%) than non-carriers (5.4%), although efficacy was consistent across genotypes [128]. The gene discussed is APOE; the disease is Alzheimer disease.